Search
Mesoblast Ltd
MESOAdd to Watchlist
14.090USD
+0.560+4.14%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.82BMarket Cap
LossP/E TTM
More Details of Mesoblast Ltd Company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Mesoblast Ltd Info
Ticker SymbolMESO
Company nameMesoblast Ltd
IPO dateDec 16, 2004
CEOItescu (Silviu)
Number of employees81
Security typeDepository Receipt
Fiscal year-endDec 16
AddressL 38 55 Collins St
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3000
Phone61396396036
Websitehttps://www.mesoblast.com/
Ticker SymbolMESO
IPO dateDec 16, 2004
CEOItescu (Silviu)
Company Executives of Mesoblast Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+42.41%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Horst, Ph.D.
Mr. Justin Horst, Ph.D.
Head - Manufacturing
Head - Manufacturing
--
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+42.41%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
FAQs
Who are the top five shareholders of Mesoblast Ltd?
The top five shareholders of Mesoblast Ltd are: Dr. Eric A. Rose, M.D.
How many institutions hold shares of Mesoblast Ltd (MESO)?
As of 2026Q1, 144 institutions hold shares of Mesoblast Ltd, with a combined market value of approximately 3.95M, accounting for 3.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -909190.00.